Health care utilization and costs associated with acute exacerbation of fibrosing interstitial lung disease in the United States: A retrospective administrative claims database analysis

Key Points

• To evaluate the health care utilization and costs associated with acute exacerbation events of fibrosing interstitial lung disease (ILD).
• Conducted a retrospective analysis using an administrative claims database.
• Compared health care utilization and costs between patients with and without acute exacerbation events.
• Matched patients based on relevant demographics and clinical characteristics.
• Patients with acute exacerbation events had significantly higher health care utilization.
• Total costs for patients experiencing exacerbations were markedly greater than those without.
• Findings highlight the financial and resource burden related to acute exacerbation of fibrosing ILD.